Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center

Calapkulu M., CANDER S., ÖZ GÜL Ö., ERSOY C.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, vol.13, no.1, pp.284-288, 2019 (ESCI) identifier identifier identifier


Introduction: Dapagliflozin is an antidiabetic drug that has been used as a member of the new antidiabetic drug group that acts by inhibiting SGLT-2 and increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin on glycemic control and anthropometric measurements were investigated retrospectively.